NeuroSense Therapeutics Ltd (NRSN) Actualités

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy...

Form POS AM - Post-Effective amendments for registration statement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update PR Newswire CAMBRIDGE...

Form POS AM - Post-Effective amendments for registration statement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS...

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences PR Newswire CAMBRIDGE, Mass...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline...

NeuroSense Therapeutics to Participate in BIO-Europe Fall

NeuroSense Therapeutics to Participate in BIO-Europe Fall PR Newswire CAMBRIDGE, Mass., Nov. 1, 2023...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense CEO Provides Q3 2023 Update

NeuroSense CEO Provides Q3 2023 Update PR Newswire CAMBRIDGE, Mass., Oct. 17, 2023 Phase 2b ALS topline...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model

NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model PR...